S1PR2 ANTAGONISTS AND USES THEREFOR
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are compounds which contain bioisosteric replacements of the urea group of JTE-013 and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.
1 .- 59 . (canceled)
60 . A compound of formula (IX),
wherein
R 1 is C 1 -C 12 alkyl;
R 2 , R 3 , and R 4 are each independently hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 perhaloalkyl, C 1 -C 4 perhaloalkoxy, amino, mono- or di-C 1 -C 4 alkylamino, C 3 -C 7 cycloalkyl or C 3 -C 7 cycloalkyloxy;
R 3 and R 4 can be positioned at h, i or j, but not simultaneously at the same position;
each instance of R 5 is independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 perhaloalkyl, C 1 -C 4 perhaloalkoxy, amino, mono- or di-C 1 -C 4 alkylamino, C 3 -C 7 cycloalkyl, and C 3 -C 7 cycloalkyloxy;
n is 0, 1, 2, 3 or 4;
X is NR a , CH 2 , or —C(═O)—, wherein each instance of R a is independently selected from hydrogen and C 1 -C 3 alkyl;
Y 1 and Y 2 are each independently selected from NR a , CH 2 , and O; and
Z is any geometric isomer of a gratin selected from one of the following:
or any pharmaceutically acceptable salt thereof.
61 . A pharmaceutical composition comprising the compound of claim 60 and a pharmaceutically acceptable carrier.
62 . A method of treating a retinopathy, comprising administering the compound of claim 60 to a subject in need thereof.
63 . The method of claim 62 , wherein the retinopathy is selected from the group consisting of diabetic retinopathy, macular degeneration, hypertensive retinopathy, radiation retinopathy, solar retinopathy, retinopathy of prematurity (ROP), Norrie disease (ND), familial exudative vitreoretinopathy (FEVR), Coats' disease, sickle cell retinopathy, and retinitis pigmentosa.
64 . The method of claim 63 , wherein the retinopathy is FEVR.
65 . A method of treating a disease characterized by insufficient angiogenesis, comprising administering the compound of claim 60 to a subject in need thereof.
66 . The method of claim 65 , wherein the disease is selected from the group consisting of atherosclerosis, hypertension, diabetes, restenosis, pre-eclampsia, menorrhagia, neonatal respiratory distress, pulmonary fibrosis, nephropathy, osteoporosis, amyotrophic lateral sclerosis, stroke, and Alzheimer's disease.
67 .- 74 . (canceled)
75 . The method of claim 62 , wherein the compound is of formula V:
76 . The method of claim 75 , wherein
R 1 is CH 3 ; and
R 2 is CH 3 .
77 . The method of claim 76 , wherein
R 3 is H; and
R 4 is C 1 -C 6 alkyl.
78 . The method of claim 77 , wherein
R 4 is CH(CH 3 ) 2 .
79 . The method of claim 78 , wherein
R 5 is halogen.
80 . The method of claim 79 , wherein
R 5 is Cl; and
n is 2.
81 . The method of claim 62 , wherein
R 1 is CH 3 ;
R 2 is CH 3 ;
R 3 is H;
R 4 is CH(CH 3 ) 2 ;
R 5 is Cl; and
n is 2.
82 . The method of claim 62 , wherein the compound is selected from the group consisting of:
83 . The compound of claim 60 , wherein Z is not —C(═O)—.
84 . The compound of claim 60 , wherein X is not —NH—.
85 . The compound of claim 60 , wherein R 3 and R 4 are not isopropyl.
86 . The compound of claim 60 , wherein
Z is —C(═O)—;
R 3 or R 4 is isopropyl; and
X is not —NH—.
87 . The compound of claim 60 , wherein
Z is —C(═O)—;
X is —NH—; and
one of R 3 and R 4 is not isopropyl.